Skip to main content
. 2010 Oct;161(4):911–924. doi: 10.1111/j.1476-5381.2010.00950.x

Figure 2.

Figure 2

BML-111 inhibits 6 h zymosan-induced oedema formation and neutrophil migration. Pretreatment with BML-111 (200 ng per cavity; i.art.) 60 min before i.art. injection of zymosan (500 µg per cavity) inhibited zymosan-induced oedema formation (A), total leucocyte (B) and neutrophil influx (C) into the knee joint cavity of C57BL/6 mice. The control group was injected with the same volume of sterile saline. Knee joint diameter was evaluated with a digital caliper, and knee synovial cells were recovered 6 h after zymosan stimulation. Results are expressed as the mean ± SEM from at least six animals per group. *P≤ 0.05, significant differences between stimulated (zymosan) and non-stimulated groups; +P≤ 0.05, significant differences between treated (BML-111) and untreated groups.